Royal Marsden NHS Foundation Trust

Researchers developed an AI test that can predict which men with high-risk prostate cancer will benefit most from abiraterone treatment by analyzing tumor images.

IMU Biosciences has adopted Curiox's Pluto Workstation to support large-scale immune phenotyping within the £21.9 million MANIFEST consortium, the UK's largest immune profiling initiative.

An international Phase 3 trial shows pembrolizumab (Keytruda) added to standard therapy extends disease-free survival from 30 to 51.8 months in patients with locally advanced head and neck cancer.

AstraZeneca's experimental drug camizestrant reduced the risk of disease progression or death by 56% in patients with hormone receptor-positive, HER2-negative breast cancer when guided by liquid biopsy testing.

A novel three-drug combination of inavolisib, palbociclib, and fulvestrant significantly extends progression-free survival in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.

• A novel three-drug combination, including inavolisib, has demonstrated a doubling of survival time in patients with advanced breast cancer compared to standard treatments. • The international trial involved 325 patients, many with cancer spread to multiple organs, highlighting the potential of this regimen in challenging cases. • The combination therapy includes inavolisib along with two drugs already available, potentially facilitating quicker adoption into clinical practice. • Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust led the study, marking a significant advancement in breast cancer treatment.

The UK government is investing in new technologies, including AI, to improve cancer detection and treatment, aiming to boost the life sciences industry.